C
annabis is the most commonly used illicit drug in the world (1) . Most people who use it come to no harm. However, it has become apparent in recent years that cannabis use is a risk factor for the development of schizophrenia-like psychotic disorders (2, 3) . Why certain individuals develop psychosis when their peers, who smoke similar amounts of cannabis, remain well is unclear. One suggestion is that such individuals may carry some genetic susceptibility (4, 5) . Should the genes underlying such susceptibility be identified, this would be of considerable public health importance.
One candidate for a gene ϫ cannabis interaction is the AKT1 gene, which has been associated with schizophrenia in some but not all studies (6 -8) . The AKT1 gene is an attractive candidate because it codes for a protein kinase that forms an integral part of the dopamine receptor signaling cascade in the striatum (9) . Moreover, in vivo administration to mice of delta-9-tetrahydrocannabinol (delta-9-TCH), the active ingredient in cannabis, activates this signaling cascade via AKT1 phosphorylation (10, 11) . Furthermore, van Winkel et al. (12) studied 801 patients with schizophrenia and 740 of their siblings and reported that subjects who carried two copies of the C allele of the rs2494732 polymorphism of the AKT1 gene were especially at risk of schizophrenia and schizotypy, respectively, if they used cannabis. In a separate study, van Winkel et al. (13) also reported an AKT1-cannabis interaction on cognitive performance. Among psychotic patients who used cannabis, carriers of the AKT1 rs2494732 C/C genotype did significantly worse on a test of sustained attention compared with T/T carriers (13) . Moreover, a neuroimaging study showed that healthy subjects carrying the dopamine transporter 9-repeat and the AKT1 rs130233 G/G genotype had the greatest psychotic response and striatal activation following administration of delta-9-THC (14) .
A recent critical review of gene ϫ environment (G ϫ E) research in psychiatry concluded that direct replications deserve more attention than novel findings or indirect replications (15) . We therefore set out to directly test the veracity of the AKT1 rs2494732 ϫ cannabis interaction in a sample of patients with their first episode of psychosis and healthy control subjects in south London. Because of this a priori hypothesis, rs2494732 was the only locus genotyped and tested for interaction with cannabis use. refused to participate and 596 patients experiencing their first episode of psychosis were successfully recruited into the study. The two most common reasons for refusal were a lack of interest in the research and the length of the full assessment.
Over the same time frame, from the area served by the same mental health units, we recruited a sample of 333 healthy control subjects, aged 18 to 65 years, which was broadly similar to the local population in terms of ethnicity, educational attainment, and employment status (18) , using internet and newspaper advertisements and distribution of leaflets at train stations, shops, and job centers. None of the material used for advertising mentioned cannabis or illicit drug use. Volunteers willing to take part in the study were administered the Psychosis Screening Questionnaire (19) and were excluded if they met criteria for a psychotic disorder or if they reported a previous diagnosis of psychotic illness.
Further details on the age distribution of the samples and on the diagnostic breakdown of the cases are available in Tables S1 and S2 in Supplement 1.
The data presented in this study are based on the 489 firstepisode psychosis patients (82% of the total recruited) and 278 control subjects (83% of the total recruited) on whom we were able to obtain both a history concerning cannabis use and DNA samples.
General Assessment and Data on Exposure of Interest
Sociodemographic data (age, gender, self-reported ethnicity, level of education attainment, and employment status) on cases and control subjects were collected using the Medical Research Council Social Scale (20) . Participants were asked if they had ever smoked tobacco, and if they drank alcohol, their weekly alcohol unit consumption was recorded. A detailed history of illicit drug use (cannabis, stimulants, and any other recreational drug) was taken using the Cannabis Experience Questionnaire modified version (21) . The two measures of exposure to cannabis use included in the analyses were: 1) lifetime history of cannabis use, i.e., had the subject ever used cannabis at any point in the lifetime (No ϭ 0; Yes ϭ 1); and 2) lifetime frequency of cannabis use, i.e., the frequency that characterized the subject's most consistent pattern of use (No ϭ 0; at weekends or less frequently ϭ 1; everyday ϭ 2).
Genotyping
DNA was obtained from all participants that completed the assessment described above (489 cases and 278 control subjects). Seventy-five percent of DNA samples used originated from blood and 25% from cheek swabs. DNA extraction was performed using standard phenol-chloroform methods.
As the purpose of the study was to explicitly test for interaction at a specific site within AKT1, genotyping focused exclusively on the van Winkel single nucleotide polymorphism (SNP), rs2494732. Off the shelf Taqman assays for this polymorphism are available as a kit, at http://www.appliedbiosystems.com. The specific assay format used can be identified by inputting the corresponding assay ID (C_16191608_10). Genotype calls were discriminated based on algorithmic membership of three clusters representing homozygote T/T, heterozygote C/T, and homozygote C/C genotype classes. A comparison of genotype results for 360 individuals with overlapping blood and cheek swab DNA revealed there was 100% concordance between blood-and cheek-derived genotype data.
Validation of Self-report of Ethnicity
To confirm self-report of ethnicity, genetic ancestry was derived using a panel of 57 ancestry informative genetic markers. These were genotyped using iPLEX technology developed for the MassArray platform (Sequenom Inc., San Diego, California). Further information on the makeup of the marker panel is available on request. Ancestry scores were derived using the program Structure (22) to implement a model-based (Markov Chain Monte Carlo) clustering algorithm. Having determined the best solution for K (the probable true number of underlying genetic groups) in initial analyses, individuals who scored between 96% and 100% for genetic cluster membership were used to create a three-way ancestral axis based on Black African (n ϭ 81), European Caucasian (n ϭ 118), and Asian (n ϭ 16) ancestry. These reference groups were used to index genetic ancestry for the remaining sample ( Figure 1 ). Eighty-three percent of participants had information on both self-reported ethnicity and ancestry markers. Using 95% to define the cutoff point for cluster membership resulted in the genetic validation of 241 selfreported ethnicities. The level of overall agreement between selfreported and genetic ethnicities (96%) was reassuringly high.
Ethics
This study was part of the GAP study, which was granted ethical approval by the South London and Maudsley and Institute of Psychiatry Local Research Ethics Committee. All cases and control subjects included in the study gave informed written consent, signing the consent document, to the publication of data originating from the study.
Data Analysis
Data were recorded in SPSS version 15 and analyzed using Stata 11 (Stata, College Station, Texas). Based on the existing literature, a history of 1) ever having used cannabis (referred to hereafter as lifetime cannabis use) and 2) lifetime frequency of use were the main environmental measures of interest. These were analyzed in conjunction with rs2494732. Genotypes at this locus were coded (for initial tests of main effects) to reflect the allele dosage of the SNP of interest selected in accordance with the original report (12) : T/T ϭ 0; C/T ϭ 1; C/C ϭ 2. Additional sociodemographic and lifestyle variables (such as ethnicity and other substance misuse) were modeled as potential confounders. Chi-square tests and t tests (or the nonparametric equivalent of these, the Mann-Whitney U test) were used to test for association between potential confounders and both presence of psychotic disorder and genotype. Further, associated with AKT1 genotype in control subjects (a signature of gene ϫ environment correlation).
Finally, a logistic regression was used to test for association of candidate genotype and presence of a psychotic disorder after adjusting for various covariates (e.g., gender, ethnicity, and tobacco use), along with either history of lifetime cannabis use or lifetime frequency of use. Analyses were run separately for each exposure and then including an interaction term between the exposure and genotype. The interaction model used examined whether the relationship between AKT1 rs2494732 genotype and presence of psychosis differed as a function of having a history of cannabis use and also explored the possibility of a relationship with frequency of use.
Odds ratios (OR) of psychosis among carriers of the AKT1 rs2494732 C/T and C/C genotypes compared with the T/T genotype, among people with different exposures to cannabis, were calculated from the estimates provided by the model.
Results
The sample consisted of 489 first episode of psychosis cases (FEP) and 278 control subjects. First episode of psychosis cases were significantly younger (mean age 27.7 years; SD 8.4) than control subjects (mean age 30.2 years; SD 9.5; p Ͻ .001) and, as expected, had a mean premorbid IQ of 6.1 points lower (p Ͻ .0001). First episode of psychosis patients were also more likely to belong to the Black African/Caribbean group (p Ͻ .001) than control subjects (Table 1) .
We obtained AKT1 rs2494732 genotyping data on 485 of 489 FEP and on 276 of 278 control subjects, with an overall call rate of 99%. We found no significant difference in AKT1 rs2494732 allelic distribution by gender ( 2 ϭ 4.12; p ϭ .128) or between FEP and control subjects ( 2 ϭ 1.25; p ϭ .535). In addition, we found no difference in the frequency of the AKT1 rs2494732 polymorphism across ethnic groups ( 2 ϭ 3.01; p ϭ .87). Genotypes at rs2494732 were in HardyWeinberg equilibrium within ethnically stratified control subjects (p ϭ .639).
Drug Consumption
More than two thirds (68.6%) of the FEP patients had a history of smoking tobacco compared with 46.8% of the control subjects ( 2 ϭ 9.3; p Ͻ .001). However, the two groups did not differ in the number of alcohol units consumed weekly ( 2 ϭ 6.4; p ϭ .095), the prevalence of life time cannabis use ( 2 ϭ .3; p ϭ .567), or on the use of stimulant drugs ( 2 ϭ 2.1; p ϭ .146). The proportion of FEP (36.2%) who reported current cannabis use was slightly, but nonsignificantly, higher ( 2 ϭ 3.0; p ϭ .085) than control subjects (27.1%). We measured the reliability of the self-reported data on current user status in a random sample of 56 cases, carrying out a urinary drug screening. Of the 56 cases tested, 34 had reported they were not current users; 32 of these (88%) had a negative urinary drug screening; only 2 tested positive and these were excluded from the analyses.
Among those who had a history of lifetime cannabis use, FEP were more likely than control subjects to be male ( 2 ϭ 11.8; p ϭ .001), to be younger (mean age 26.9 years, SD 7.8 vs. mean age 29.7 years, SD 8.6; t ϭ 3.1; p Ͻ .001), and to report daily use (73.9% vs. 39.5%; 2 ϭ 35.8; p Ͻ .001) ( Table 2) .
Case-Control G ؋ E Analyses
There was no evidence of a correlation between the AKT1 rs2494732 genotype and lifetime cannabis use ( 2 ϭ .7, p ϭ .692) or lifetime frequency of use ( 2 ϭ 4.4; p ϭ .352). A multivariable logistic regression adjusting for gender, ethnicity, and tobacco use (n ϭ 598) showed a significant interaction between lifetime cannabis use and genotype (likelihood ratio test ϭ 8.54; p ϭ .014). This suggests that the effect of lifetime cannabis use on the likelihood of suffering from a psychotic disor- der differed according to rs2494732 genotype. Among those who had never used cannabis, there was no significant change in risk associated with rs2494732 genotype. In contrast, among subjects having a lifetime history of cannabis use, carriers of the C/C genotype showed a greater than twofold increased odds of having psychotic disorder (OR ϭ 2.18; 95% confidence interval: 1.10, 4.31) when compared with T/T carriers ( Figure 2 ; Table 3 ). In a second logistic regression, which again controlled for the same covariates as above (n ϭ 511), we found the interaction between the AKT1 rs2494732 genotype and lifetime frequency of cannabis use to be significant at greater than the 5% level (likelihood ratio test ϭ 13.39; p ϭ .010). Among subjects who had never used cannabis, there was again no significant association between genotype and presence of a psychotic disorder. In contrast, among both occasional and daily cannabis users, the OR for C/C carriers indicated an increase in the probability of suffering a psychotic disorder in comparison with those with the T/T genotype, but only among daily cannabis users did the increased odds of psychosis shown by C/C carriers reach significance (OR ϭ 7.23; 95% confidence interval: 1.37, 38.12) (Figure 3 ; Table 4 ).
Discussion
Although only a minority of cannabis users ever develop a psychotic disorder, its widespread use means that it is important to establish why some individuals develop the illness. Our previous study showed that the risk of psychosis depends, in part, on how frequently people use cannabis (23) . Our present findings confirm the recent report of the role played by the variation at the rs2494732 locus of AKT1 in influencing the risk of cannabis use in causing psychosis (12) . This opens up the possibility of identifying those who should avoid the use of cannabis.
The biology of cannabis-induced psychosis is only partly understood (24) . The active ingredient of cannabis, delta-9-TCH, is responsible for its psychotomimetic effects. Delta-9-tetrahydrocannabinol inhibits, via cannabinoid receptor type 1 activation, the release of glutamate onto gamma-aminobutyric acidergic neurons that project from the nucleus accumbens to the ventral tegmental area. These neurons normally exert an inhibitory effect on the firing of dopamine neurons that project back to the nucleus accumbens (25) . Thus, their inhibition causes increased dopamine release in the striatum, which is implicated in the pathogenesis of psychotic symptoms (26, 27) .
It seems logical to attempt to explain differences in the individual response to the psychotogenic effects of cannabis in terms of individual genetic makeup, particularly the subset of genes involved in dopamine pathways. However, an early report that variation at the COMT gene might play a role remains controversial (4, 28) .
Nevertheless, genes that regulate signaling pathways and impact on dopamine transmission may still be plausible candidates for such a G ϫ E interaction. For instance, the protein encoded by the gene AKT1 is a serine/threonine kinase, whose main function is the phosphorylation and consequent inactivation of glycogen synthase kinase (GSK-3) (26) . AKT1 and GSK-3 are known to be at the heart of a signal transduction framework, initiated by dopamine D2 signaling, which ultimately influences a wide range of cellular processes, including apoptosis, cell survival, and metabolism (29) . A recent neuroimaging study by Blasi et al. (30) showed that AKT1/ DRD2 polymorphisms are epistatically associated with attentional processing and response to olanzapine treatment in schizophrenia. These findings further support the role of the AKT1 pathway in regulating D2 receptor dependent dopamine signaling and its role in psychotic disorders.
Moreover, in vivo studies have reported that delta-9-THC can induce phosphorylation of AKT1 with its activation in several brain areas, including the striatum (31) . As the activation of the AKT1/ GSK-3 cascade is known to impact on D2 receptor signaling (32, 33) , it is plausible that delta-9-THC might increase liability to psychosis via this pathway. Our findings need to be considered in light of some potential limitations.
First, it is possible that our method of control subject recruitment could have biased our findings. However, there is no sugges- tion that we undersampled cannabis users. Indeed, the proportion of control subjects that had ever used cannabis (63%) was higher than the national average (47%) for similar age groups. This is probably a reflection of the higher prevalence of cannabis use in the local community compared with the United Kingdom as a whole (34) . Almost equal prevalence of exposure in both cases and control subjects increases the power of G ϫ E analyses. It is possible that our control subject recruitment strategy biased our sample toward one of mild cannabis users. Our advertising strategy included internet and local newspapers ads, as well as distribution of leaflets at local shops, job centers, and community centers. There is no evidence that such methods of advertising are more likely to bias toward better functioning and socially adjusted subjects; indeed, the opposite might happen. Therefore, it seems unlikely that the difference in frequency of cannabis use by cases and control subjects is driven by a recruitment bias. Second, our sample is multiethnic. This could be limiting, given that HapMap reports the following differences in allele frequency between populations: Black African: .42, White Caucasian: .46, Asian (Chinese and Japanese): .62 (35) . To account for the possibility of population stratification, we controlled for the potential confounding effect of ethnicity. However (as already reported), we could find no actual difference between the frequency of rs2494732 alleles across the main (black and white caucasian) ethnic groups (in cases and control subjects) ( Table 5 ). This is consistent with HapMap data and the marginal difference between the minor allele frequency estimates themselves in African and Caucasian populations (.42 vs. .46), compared with Chinese and Japanese. Our sample comprised just three cases and two control subjects of Chinese and Japanese origin. Thus, latent differences in allele frequency at rs2494732 were very unlikely to have biased the outcome of the study.
Another possible limitation is the lack of evidence that variation at the locus of our AKT1 SNP of interest (rs2494732) affects the signaling pathway. There are no available data describing if and how changes in the AKT1 genotype for rs2494732 impact on the protein function. Nevertheless, HapMap 3 preliminary data report (36) that rs2494732 is 702 base pairs apart from rs1130233, a SNP that has been shown to affect AKT gene messenger RNA expression (37) . The R 2 (a measure of correlation) between these two SNPs (rs2494732 and rs1130233) is .95, which genetically speaking is very high and suggestive of linkage dysequilibrium. This might explain why the studies that have tested for an AKT1-cannabis interaction on either a psychosis outcome (12, 14) or altered cognitive performance (13) have converged in the same direction whether selecting rs2494732 or rs1130233 as the genetic variant of interest. Finally, we relied on self-report concerning cannabis use. We did, however, check the urine of a subsample and found concordance of the two methods in a very high proportion of cases. Furthermore, any inaccuracy would have diminished our likelihood of finding an interaction effect.
The main strength of our study is its design. A case-control strategy is the gold standard design to test G ϫ E interaction hypotheses (38) . In addition, in keeping with good methodological practice for a G ϫ E replication study (39), we genotyped only the candidate genetic variant and selected the environmental exposure according to the priori hypothesis suggested by the original report (12) we set to replicate; thus, we avoided multiple testing.
Our study sample size had 70% power to detect, at a 5% significance level, the twofold increased likelihood of psychotic disorder in AKT1 rs2494732 C/C carriers with history of cannabis use compared with T/T carriers. Importantly, it had over 80% power to detect the sevenfold increase in OR we report in AKT1 rs2494732 C/C carriers who used cannabis daily compared with the T/T ones. In the original report, van Winkel et al. (12) also noted a significant interaction between frequency of use, as a measure of exposure to cannabis, and AKT1 rs2494732, which further indicates that our results are a true replication.
In conclusion, our findings confirm the moderating role of the AKT1 rs2494732 C/C genotype on the effect of cannabis use in increasing the risk of a psychotic disorder.
Nevertheless, genome-wide association studies have shown that the term polygenic can refer to hundreds or thousands of common variants (40) . Therefore, it is likely that AKT1 rs2494732 contributes to susceptibility to the psychotogenic effect of cannabis together with other genetic variants. Indeed, a recent report shows that five of the novel schizophrenia loci identified by the Schizophrenia Psychiatric Genome-Wide Association Study Consortium impact on the AKT pathway and concludes that these genes may be involved in "converting information from the environment to this biological system" (8) . Identifying such gene variants and the biological pathways they influence can improve our understanding on how they exert their effect on an individual's liability to psychosis in the presence of particular environmental risk factors. This should help us to design health, educational, and screening campaigns tailored to reach those groups at particular risk.
